What is Zembrace® SymTouch®

Zembrace® SymTouch® is a prescription medicine used to treat acute migraine headaches with or without aura in adults 18 years of age and older who have been diagnosed with migraine.

Zembrace® SymTouch® is not used to prevent or decrease the number of migraines you have.

Do not take Zembrace® SymTouch® if you have hemiplegic migraines or basilar migraines. This is not the only reason not to take Zembrace® SymTouch®. See Important Safety Information and speak with your healthcare provider for more information.


Fast and powerful1,2

In as little as 10 minutes, you may get migraine pain relief (17% of patients for sumatriptan 3 mg vs. 5% for placebo). One study showed that 60% of people experienced pain relief within 2 hours of use (vs. 21% for placebo).

The most common side effects of Zembrace® SymTouch® include pain and redness at your injection site; tingling or numbness in your fingers or toes; dizziness; warm, hot burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy or tired.1


  • Smallest needle in a sumatriptan pen3 (auto-injector)
  • Simple, two-step injection process1,4
  • No refrigeration needed††

Zembrace® SymTouch® for as little as $0*

Eligible, commercially insured patients may pay as little as $0* per prescription, per month.

Zembrace® SymTouch® is simple to use

Watch the Instructions for Use video to learn how to use Zembrace® SymTouch®.

Share your story

Share your story to help bring awareness to others who suffer from migraine.

Please contact us if you are:
– Currently treating your migraines with Zembrace® SymTouch®.
– At least 18 years of age.
– Live in the United States.


  1. Zembrace SymTouch [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: February 2021.
  2. Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.
  3. Data on file. Chatham, NJ: Tonix Medicines, Inc.: 2021.
  4. Brand-Schieber E, Munjal S, Kumar R, et al. Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients. Med Devices (Auckl). 2016;9:131-137.